About PharmaKodex
PharmaKodex is a Healthcare company based in Chippenham (United Kingdom) founded in 2006, and was acquired by Orexo in February 2009. It operates as a proprietary drug delivery technologies are developed for medicine reformulation. PharmaKodex has raised $13.46 million across 1 funding round from investors including Orexo, Apposite Capital and SR One. The company has 2 employees. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is PHARMAKODEX LIMITED. Its competitors include Jazz Pharmaceuticals, GSK, Avidity Biosciences, Lundbeck and Kriya Therapeutics and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
PharmaKodex was spun out from Vectura Group plc and Unilever to develop the proprietary formulation and delivery product assets from both companies. PharmaKodex is PharmaKodex exploits its proprietary drug delivery and formulation technologies to develop improved medicines using existing drug molecules, for example by providing faster acting, safer andor more effective products as well as identifying novel synergistic combinations, which are protected by strong intellectual property. PharmaKodex has two main delivery technology families derived from its original parent companies and further developed by the company. First, its oral platform, Accustar comprises a number of novel technologies including: i) Solid Syrup for improved mouthfeel and capable of rapid dissolution as well as controlled drug delivery; ii) Taste Transformation for neutralizing bitter tasting drugs without delaying absorption and iii) Xerosol aimed at improving transmucosal drug delivery via the sublingual or buccal routes. Second, its transdermal platform, Pandermal, is a patch-free unit dose transdermal delivery system capable of delivering high drug payloads in metered doses and with controllable skin fluxes. In addition, PharmaKodex has two enabling technologies and a novel oral controlled-release platform. All of the intellectual property associated with these technologies became the property of Orexo, which acquired the company in Feb 2009
- Headquarters Chippenham, United Kingdom
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website pharmakodex.com
- Social LinkedIn
- Acquired by Orexo (Feb 2009)
- Legal Name Pharmakodex Limited
Funding Insights of PharmaKodex
PharmaKodex has successfully raised a total of $13.46M through 1 strategic funding round. The most recent funding activity was a Series B round of $13.46 million completed in November 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.46M
- Total Rounds 1
- Last Round Series B — $13.46M
- First Round $13.46M
(Nov 2006)
- Investors Count 2
All 1 funding rounds of PharmaKodex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2006 | $13.46M | Series B | – | Apposite Capital, SR One | – |
3 investors in total: 3 institutional.
Investors in PharmaKodex
PharmaKodex has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Orexo, Apposite Capital and SR One.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare impact investments are managed by Apposite Capital. | – | appositecapital.com | London, United Kingdom | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
Therapeutics for mental illness and substance use disorders are developed. | 1995 | orexo.com | Uppsala, Sweden |
Investor details for PharmaKodex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of PharmaKodex
3 dated milestones of PharmaKodex across 3 years, from founding to its latest funding, stage changes and deals.
- Founded PharmaKodex is founded.
- Funding First funding round of $13.5M.
- Exit Acquired by Orexo.
Competitors of PharmaKodex
PharmaKodex has 9 listed competitors in our database, 7 of them funded. They include Jazz Pharmaceuticals, GSK, Avidity Biosciences, Lundbeck and Kriya Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| gsk.com | 1715 | Brentford, United Kingdom | – | 90,913 | Developer of pharmaceuticals and vaccines for various therapeutic areas | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| lundbeck.com | 1915 | Copenhagen, Denmark | – | 393 | Drugs for CNS disorders are developed and advanced. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| biohavenpharma.com | 2014 | New Haven, United States | $84.1M | 932 | Therapies for neurological and neuropsychiatric diseases are developed. | |
| karunatx.com | 2009 | Boston, United States | $132.1M | 339 | Therapies for psychosis and cognitive impairment are developed. |
Detailed competitors of PharmaKodex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as PharmaKodex (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PharmaKodex
PharmaKodex was founded in 2006.
PharmaKodex is headquartered in Chippenham, United Kingdom.
PharmaKodex is a funded company, having raised a total of $13.46M across 1 funding round to date. The company's 1st funding round was a Series B of $13.46M, raised on Nov 2006.
PharmaKodex has 2 employees.
PharmaKodex was spun out from Vectura Group plc and Unilever to develop the proprietary formulation and delivery product assets from both companies. PharmaKodex is PharmaKodex exploits its proprietary drug delivery and formulation technologies to develop improved medicines using existing drug molecules, for example by providing faster acting, safer andor more effective products as well as identifying novel synergistic combinations, which are protected by strong intellectual property. PharmaKodex has two main delivery technology families derived from its original parent companies and further developed by the company. First, its oral platform, Accustar comprises a number of novel technologies including: i) Solid Syrup for improved mouthfeel and capable of rapid dissolution as well as controlled drug delivery; ii) Taste Transformation for neutralizing bitter tasting drugs without delaying absorption and iii) Xerosol aimed at improving transmucosal drug delivery via the sublingual or buccal routes. Second, its transdermal platform, Pandermal, is a patch-free unit dose transdermal delivery system capable of delivering high drug payloads in metered doses and with controllable skin fluxes. In addition, PharmaKodex has two enabling technologies and a novel oral controlled-release platform. All of the intellectual property associated with these technologies became the property of Orexo, which acquired the company in Feb 2009.
PharmaKodex's top competitors include Jazz Pharmaceuticals, Biohaven Pharmaceutical and Avidity Biosciences.
PharmaKodex has 3 investors. Key investors include Orexo, Apposite Capital, and SR One.
PharmaKodex operates through Pharmakodex Limited.
Yes. PharmaKodex was acquired by Orexo in February 2009.